Nadia Amellal
Impact in
- Otorhinolaryngology top 0.02%
- Head and Neck Cancer Studies
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
Papers in
-
- Head and Neck Cancer Studies 20
- Oncology 48
- Colorectal Cancer Treatments and Studies 35
- Cancer Treatment and Pharmacology 20
- Peptidase Inhibition and Analysis 6
- Co-authors
- José BaselgaRicardo HittJan B. VermorkenJ. GiraltJames A. BonnerJacek JassemPaul M. HarariEric K. Rowinsky
- Journals
- Journal of Clinical Oncology (26 papers)Annals of Oncology (9 papers)ESMO Open (5 papers)New England Journal of Medicine (3 papers)British Journal of Cancer (2 papers)
- Partner nations
- FranceSpainUnited States
In The Last Decade
Nadia Amellal
57 papers receiving 8.8k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Otorhinolaryngology 4.2k
- Oncology 5.3k
- Pulmonary and Respiratory Medicine 4.0k
- Cancer Research 847
- Surgery 2.4k
Countries citing papers authored by Nadia Amellal
This map shows the geographic impact of Nadia Amellal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Amellal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Amellal more than expected).
Fields of papers citing papers by Nadia Amellal
This network shows the impact of papers produced by Nadia Amellal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Amellal. The network helps show where Nadia Amellal may publish in the future.
Co-authors
The 25 scholars most cited alongside Nadia Amellal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 4 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 1 | |
| 5 | Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer Hit paper breakdown → | 2023 | 183 |
| 6 | 2023 | 3 | |
| 7 | 2022 | 9 | |
| 8 | 2022 | 21 | |
| 9 | 2021 | 11 | |
| 10 | 2020 | 40 | |
| 11 | 2020 | 15 | |
| 12 | 2019 | 111 | |
| 13 | 2019 | 8 | |
| 14 | 2017 | 2 | |
| 15 | 2017 | 14 | |
| 16 | 2016 | 4 | |
| 17 | 2015 | 16 | |
| 18 | 2008 | 152 | |
| 19 | Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2006 | 3707 |
| 20 | 2005 | 139 |
About Nadia Amellal
Nadia Amellal is a scholar working on Otorhinolaryngology, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Hepatology, having authored 60 papers that have together received 9.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (35 papers), Cancer Treatment and Pharmacology (20 papers), Head and Neck Cancer Studies (20 papers), Lung Cancer Treatments and Mutations (17 papers), Genetic factors in colorectal cancer (13 papers), Gastric Cancer Management and Outcomes (10 papers), Peptidase Inhibition and Analysis (6 papers) and Economic and Financial Impacts of Cancer (4 papers). The work is most often cited by research in Otorhinolaryngology (4.2k citations), Oncology (5.3k citations), Pulmonary and Respiratory Medicine (4.0k citations), Cancer Research (847 citations) and Surgery (2.4k citations). Nadia Amellal has collaborated with scholars based in France, Spain and United States. Frequent co-authors include José Baselga, Ricardo Hitt, Jan B. Vermorken, J. Giralt, James A. Bonner, Jacek Jassem, Paul M. Harari, Eric K. Rowinsky, Roger B. Cohen and Merrill S. Kies. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, ESMO Open, New England Journal of Medicine and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.